Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.2.0.727
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Cash Flows from Operating Activities:    
Net Loss $ (18,953) $ (12,081)
Reconciliation of net loss to net cash used in operating activities:    
Depreciation and amortization 11 11
Noncash interest expense 167 555
Amortization of debt discount 84 0
Stock-based compensation expenses - Fortress 3,395 2,598
Change in fair value of investment (1,407) 0
Asset impairment loss 0 723
Unrealized gain on marketable securities 2 0
Increase (decrease) in cash resulting from changes in assets and liabilities:    
Prepaid expenses and other current assets (295) 124
Accounts payable and accrued expenses 920 (1,486)
Interest payable (2) (84)
End of term fee associated with Hercules Note 0 (398)
Other long term liabilities (624) (50)
Net Cash used in Operating Activities (16,702) (10,088)
Cash Flows from Investing Activities:    
Purchase of short- term investment 0 (295)
Purchase of long-term investment 0 (250)
Purchase of property and equipment (49) 0
Purchase of license (1,250) 0
Payment to related parties - CB Pharma Acquisition Corp (108) 0
Net Cash used in Investing Activities (1,407) (545)
Cash Flows from Financing Activities:    
Payment of Hercules Note 0 (13,655)
Proceeds from issuance of common stock 0 606
Proceeds from the exercise of stock options 216 0
Proceeds from issuance of common stock under ESPP 26 0
Payment of costs related to the issuance of Common Stock 0 (32)
Proceeds from IDB note 0 14,009
Payment of debt issue costs associated with IDB Note 0 (9)
Proceeds from NSC note 10,000 0
Payment of debt issue costs associated with NSC Note (855) 0
Transfer of restricted cash 0 (14,009)
Net Cash provided by (used in) Financing Activities 9,387 (13,090)
Net decrease in cash and cash equivalents (8,722) (23,723)
Cash and cash equivalents at beginning of period 49,759 99,521
Cash and cash equivalent at end of period 41,037 75,798
Supplemental disclosure of cash flow information:    
Cash paid for interest 80 614
Supplemental disclosure of non-cash financing and investing activities:    
Issuance of restricted stock $ 1 $ 4